Bone-Rad Therapeutics is currently in the Start-up funding stage and is seeking investment from Angels, VC and high-net-worth individuals. Inquiries should be made to:



Harry Skinner, M.D., Ph.D., President and CEO

​

• harry.skinner@bone-rad.com​

​



Bone-Rad Therapeutics' initial Seed Funding was provided by a $760,000 research grant from the Department of Defense Breast Cancer Research Program. The results of this research include:

​

• Submission of 2 patents with 37 claims

• Method for creating a P-32 radioactive bone cement

• Functional prototypes for Spine-Rad™ Cement and Spine-Rad™ Cement Mixing and Delivery System (MDS)

• Development of dosimetry models and validation in cadaver specimens

• Development of manufacturing processes and shipping requirements

• Spine-Rad™ Cement leaching studies to verify P-32 bonding to PMMA

• Bone cement compressive strength studies following therapeutic radiation dose